Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Zafgen Inc    ZFGN

ZAFGEN INC (ZFGN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
8.15(c) 8.19(c) 8.91(c) 8.13(c) 8.37(c) Last
135 795 133 012 311 606 247 514 200 717 Volume
+2.90% +0.49% +8.79% -8.75% +2.95% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -55,0 M
Net income 2017 -54,4 M
Finance 2017 78,0 M
Yield 2017 -
Sales 2018 -
EBIT 2018 -67,6 M
Net income 2018 -67,0 M
Finance 2018 123 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 0
Capitalization 230 M
More Financials
Company
Zafgen, Inc. is a biopharmaceutical company, which is engaged in the development of anti-obesity therapeutics that restores normal fat metabolism and regulatory pathways.Its product: Beloranib, which is under phase 2 clinical development as a treatment for obesity and hyperphagia in Prader-Willi... 
More about the company
Latest news on ZAFGEN INC
02/12ZAFGEN : to Present at the Leerink Partners 7th Annual Global Healthcare Confere..
AQ
02/08Zafgen to Present at the Leerink Partners 7th Annual Global Healthcare Confer..
GL
01/18Orchard Therapeutics press release
AQ
01/09ZAFGEN : tries again with obesity, rare disease drugs after setback
AQ
01/08ZAFGEN : Reports Strong Clinical Progress and Updates Outlook for 2018
AQ
01/08ZAFGEN INC : Blog Exposure - Zafgen Reports Strong Clinical Progress and Updates..
AC
01/06ZAFGEN : Reports Strong Clinical Progress and Updates Outlook for 2018
AQ
01/05ZAFGEN, INC. : Entry into a Material Definitive Agreement, Creation of a Direct ..
AQ
01/05Zafgen Reports Strong Clinical Progress and Updates Outlook for 2018  
GL
01/04ZAFGEN : Patent Issued for Methods of Treating Impaired Wound Healing (USPTO 984..
AQ
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
01:49pGet the latest news and updates for $PNTR $ZFGN $KNL $GABC $WABC automaticall.. 
02/18Zafgen $ZFGN Receives Media Sentiment Rating of 0.22  
02/18Analysts Anticipate Zafgen Inc $ZFGN Will Announce Earnings of -$0.59 Per Sha.. 
02/14$MGEN - Miragen Therapeutics, Inc. #MGEN Director Bruce Booth Acquires 545,45.. 
02/13Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Zafgen $ZFGN St.. 
More tweets
Qtime:123
News from SeekingAlpha
02/16Biotech Forum Daily Digest For January 16th 
02/15Zafgen (ZFGN) Presents At Leerink Partners 7th Annual Global Healthcare Confe.. 
02/09Key healthcare events next week (continued) 
02/05Why Zafgen's Upcoming Catalyst Is So Important 
02/02HEALTHCARE GAINERS / LOSERS AS OF 11 : 00 am (2/2/2018) 
Chart ZAFGEN INC
Duration : Period :
Zafgen Inc Technical Analysis Chart | ZFGN | US98885E1038 | 4-Traders
Technical analysis trends ZAFGEN INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 6,67 $
Spread / Average Target -20%
EPS Revisions
Managers
NameTitle
Jeffrey S. Hatfield Chief Executive Officer & Director
Thomas E. Hughes President, Chief Scientific Officer & Director
Peter Barrett Chairman
Patricia L. Allen CFO, Treasurer & Principal Accounting Officer
Dennis D. Kim Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ZAFGEN INC92.86%245
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
GENMAB4.28%11 055